Patents by Inventor Gwangseong Kim
Gwangseong Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220409565Abstract: Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.Type: ApplicationFiled: November 3, 2020Publication date: December 29, 2022Inventors: Clet NIYIKIZA, Victor Mandla MOYO, Bolin GENT, Zhenghong XU, Kaniz KHALIFA, Gwangseong KIM
-
Patent number: 11369683Abstract: The present invention relates to nanoparticles. In particular, the present invention provides nanoparticles for clinical (e.g., targeted therapeutic), diagnostic (e.g., imaging), and research applications in the field of cardiology. For example, in some embodiments, the present invention provides a method of treating (e.g., ablating) cardiac tissue, comprising: a) contacting an animal with a nanoparticle comprising a matrix, a toxic (e.g., ablative) agent (e.g., sonosensitizer, chemotherapeutic agent (e.g., doxorubicin or cisplatin), or photosensitizer), and a cardiac targeting moiety; and b) administering an activator of the toxic agent (e.g., light, chemical (e.g., pharmaceutical agent) or ultrasound) to at least a portion of the cardiac tissue (e.g., heart) of the animal to activate the toxic agent.Type: GrantFiled: December 10, 2019Date of Patent: June 28, 2022Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Jerome Kalifa, Raoul Kopelman, Uma Mahesh R. Avula, Gwangseong Kim, Yong-Eun Koo Lee, Hyung Ki Yoon
-
Publication number: 20210283055Abstract: Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.Type: ApplicationFiled: May 3, 2019Publication date: September 16, 2021Inventors: Clet NIYIKIZA, Victor Mandla MOYO, Bolin GENG, Zhenghong XU, Kaniz KHALIFA, Gwangseong KIM
-
Publication number: 20200188514Abstract: The present invention relates to nanoparticles. In particular, the present invention provides nanoparticles for clinical (e.g., targeted therapeutic), diagnostic (e.g., imaging), and research applications in the field of cardiology. For example, in some embodiments, the present invention provides a method of treating (e.g., ablating) cardiac tissue, comprising: a) contacting an animal with a nanoparticle comprising a matrix, a toxic (e.g., ablative) agent (e.g., sonosensitizer, chemotherapeutic agent (e.g., doxorubicin or cisplatin), or photosensitizer), and a cardiac targeting moiety; and b) administering an activator of the toxic agent (e.g., light, chemical (e.g., pharmaceutical agent) or ultrasound) to at least a portion of the cardiac tissue (e.g., heart) of the animal to activate the toxic agent.Type: ApplicationFiled: December 10, 2019Publication date: June 18, 2020Inventors: Jerome Kalifa, Raoul Kopelman, Uma Mahesh R. Avula, Gwangseong Kim, Yong-Eun Koo Lee, Hyung Ki Yoon
-
Patent number: 10512691Abstract: The present invention relates to nanoparticles. In particular, the present invention provides nanoparticles for clinical (e.g., targeted therapeutic), diagnostic (e.g., imaging), and research applications in the field of cardiology. For example, in some embodiments, the present invention provides a method of treating (e.g., ablating) cardiac tissue, comprising: a) contacting an animal with a nanoparticle comprising a matrix, a toxic (e.g., ablative) agent (e.g., sonosensitizer, chemotherapeutic agent (e.g., doxorubicin or cisplatin), or photosensitizer), and a cardiac targeting moiety; and b) administering an activator of the toxic agent (e.g., light, chemical (e.g., pharmaceutical agent) or ultrasound) to at least a portion of the cardiac tissue (e.g., heart) of the animal to activate the toxic agent.Type: GrantFiled: April 23, 2013Date of Patent: December 24, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Jerome Kalifa, Raoul Kopelman, Uma Mahesh R. Avula, Gwangseong Kim, Yong-Eun Koo Lee, Hyung Ki Yoon
-
Publication number: 20160334312Abstract: The present invention relates to concentrating disease causing agents, such as foodborne pathogens, from complex media to expedite their detection. In particular, the present invention relates to a method to pre-concentrate pathogens rapidly, thereby enabling earlier detection times. Primarily, the present invention utilizes an approach that can concentrate the pathogens by flowing a sample through immuno-capturing tubes (“entrapment chamber” or “chamber”) during an early pre-enrichment period. Also, the invention relates to using binding materials to trap disease causing agent that is desired to be removed from the complex media such as the blood of a patient. It also related to using lights of specific wavelength to inactivate pathogens. The light is used to activate reactive oxygen species using a photo-sensitizer or directly kill the pathogen using light of wavelength between 100 nm and 450 nm.Type: ApplicationFiled: July 28, 2016Publication date: November 17, 2016Inventors: Angelo Gaitas, Gwangseong Kim
-
Publication number: 20160058937Abstract: The present invention relates to removing disease causing agent such as pathogens from the blood of a patient. Specifically, the invention relates to using coating materials to trap disease causing agent that is desired to be removed from the blood of a patient. It also related to using lights of specific wavelength to inactivate pathogens. The light is used to activate reactive oxygen species using a photo-sensitizer or directly kill the pathogen using light of wavelength between 100 nm and 450 nm.Type: ApplicationFiled: November 9, 2015Publication date: March 3, 2016Inventors: Angelo Gaitas, Gwangseong Kim
-
Publication number: 20150328315Abstract: The present invention relates to nanoparticles. In particular, the present invention provides nanoparticles for clinical (e.g., targeted therapeutic), diagnostic (e.g., imaging), and research applications in the field of cardiology. For example, in some embodiments, the present invention provides a method of treating (e.g., ablating) cardiac tissue, comprising: a) contacting an animal with a nanoparticle comprising a matrix, a toxic (e.g., ablative) agent (e.g., sonosensitizer, chemotherapeutic agent (e.g., doxorubicin or cisplatin), or photosensitizer), and a cardiac targeting moiety; and b) administering an activator of the toxic agent (e.g., light, chemical (e.g., pharmaceutical agent) or ultrasound) to at least a portion of the cardiac tissue (e.g., heart) of the animal to activate the toxic agent.Type: ApplicationFiled: April 23, 2013Publication date: November 19, 2015Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Jerome Kalifa, Raoul Kopelman, Uma Mahesh R. Avula, Gwangseong Kim, Yong-Eun Koo Lee, Hyung Ki Yoon
-
Publication number: 20150121808Abstract: The present invention relates to removing disease material from the blood of a patient. Specifically, the invention relates to using biological binders to trap disease material that is desired to be removed from the blood of a patient.Type: ApplicationFiled: December 8, 2014Publication date: May 7, 2015Inventors: Angelo Gaitas, Gwangseong Kim
-
Patent number: 7576334Abstract: A method of measuring fluorophore excited state lifetimes comprising initiating an excitation laser pulse at a dye to excite dye molecules of the dye from a ground state to an excited state and initiating a probing pulse at the dye molecules thereby generating a first set of photoacoustic waves at a first time delay resulting in a first intensity point. The process can be repeated, optionally introducing a second excitation laser pulse, to generate a second set of photoacoustic waves at a second time delay resulting in a second intensity point. The data can be analyzed to determine a slope between the first intensity point and the second intensity point.Type: GrantFiled: March 18, 2008Date of Patent: August 18, 2009Assignee: The Regents of the University of MichiganInventors: Shai Ashkenazi, Raoul Kopelman, Russell S. Witte, Thomas D. Horvath, Gwangseong Kim
-
Publication number: 20080230717Abstract: A method of measuring fluorophore excited state lifetimes comprising initiating an excitation laser pulse at a dye to excite dye molecules of the dye from a ground state to an excited state and initiating a probing pulse at the dye molecules thereby generating a first set of photoacoustic waves at a first time delay resulting in a first intensity point. The process can be repeated, optionally introducing a second excitation laser pulse, to generate a second set of photoacoustic waves at a second time delay resulting in a second intensity point. The data can be analyzed to determine a slope between the first intensity point and the second intensity point.Type: ApplicationFiled: March 18, 2008Publication date: September 25, 2008Inventors: Shai Ashkenazi, Raoul Kopelman, Russell S. Witte, Thomas D. Horvath, Gwangseong Kim